A reporting track will now be set for all cell therapy CRIDs reported to the CIBMTR. The track will be set by the center reporting preference and infusion type.
There are five cellular therapy reporting tracks.
Standard follow up
- Applies to stand-alone non-genetically modified cell therapy infusions without a history of HCT
- Follow up schedule: 100d-6yr, 8yr, 10yr, 12yr, 14yr
- Forms: F4000, F4003, F4006, F4100, F2402 + disease forms (when applicable)
15 year follow up
- Applies to any genetically modified product (stand alone or post-HCT)
- Follow up schedule: 100 day – 15 years
- Forms: F4000, F4003, F4006, F4100, F2402 + disease forms (when applicable)
100 day only follow up
- Applies to post-HCT non-genetically modified cell therapy infusions (excludes Donor Lymphocyte Infusions (DLIs))
- Follow up schedule: 100 day only
- Forms: F4000, F4003, F4006, single F4100 at 100d, F2402 + disease forms (when applicable)
No follow up
- Applies when consent to CIBMTR Research Database has not been obtained
- Follow up schedule: none
- Forms: F4000 + F2402, disease form (when applicable)
CTRM
- Applies to cell therapy infusions for regenerative medicine indications (cardiovascular disease, musculoskeletal disorder, neurologic disease, ocular disease, pulmonary disease)
- Follow up schedule: none
- Forms: F4000, F4003, F4006
Last modified:
Sep 23, 2022